Mitsumasa Osakabe

Mitsumasa Osakabe

Auto-generated profile, based on publicly available information

Mitsumasa Osakabe

Department of Diagnostic Pathology Iwate Medical University School of Medicine Iwate Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Riuko OhashiRiuko Ohashi
Riuko Ohashi
PSPeter Schraml
Peter Schraml
SASilvia Angori
Silvia Angori
ABAashil Batavia
Aashil Batavia
NRNiels J. Rupp
Niels J. Rupp
HMHolger Moch
Holger Moch
Chromophobe renal cell carcinoma (chRCC) is a renal tumor subtype with a good prognosis, characterized by multiple chromosomal copy number variations (CNV). The World Health Organization (WHO) chRCC classification guidelines define a classic and an eosinophilic variant. Large cells with reticular cytoplasm and prominent cell membranes (pale cells) are characteristic for classic chRCC. Classic and eosinophilic variants were defined in 42 Swiss chRCCs, 119 Japanese chRCCs and in whole-slide digital images of 66 chRCCs from the Cancer Genome Atlas (TCGA) kidney chromophobe (KICH) dataset. 32 of 42 (76.2%) Swiss chRCCs, 90 of 119 (75.6%) Japanese chRCCs and 53 of 66 (80.3%) TCGA-KICH were classic chRCCs. There was no survival difference between eosinophilic and classic chRCC in all three cohorts. To identify a genotype/phenotype correlation, we performed a genome-wide CNV analysis using Affymetrix OncoScan® CNV Assay (Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA) in 33 Swiss chRCCs. TCGA-KICH subtypes were compared with TCGA CNV data. In the combined Swiss and TCGA-KICH cohorts, losses of chromosome 1, 2, 6, 10, 13, and 17 were significantly more frequent in classic chRCC (p < 0.05, each), suggesting that classic chRCC are characterized by higher chromosomal instability. This molecular difference justifies the definition of two chRCC variants. Absence of pale cells could be used as main histological criterion to define the eosinophilic variant of chRCC.

1 October 2017 in Pathology
Verified
Journal Article
Closed access
NUNoriyuki Uesugi
Noriyuki Uesugi
TSTamotsu Sugai
Tamotsu Sugai
RSRyo Sugimoto
Ryo Sugimoto
MEMakoto Eizuka
Makoto Eizuka
YFYasuko Fujita
Yasuko Fujita
TMTakayuki Matsumoto
Takayuki Matsumoto

8 March 2023 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
MTMikiya Todori
Mikiya Todori
NYNaoki Yanagawa
Naoki Yanagawa
KIKazuhiro Ito
Kazuhiro Ito
YIYuma Ito
Yuma Ito
MSMasamichi Suzuki
Masamichi Suzuki
TSTamotsu Sugai
Tamotsu Sugai
Introduction. Carcinoma with sarcomatoid components is a highly malignant tumor exhibiting both epithelial and stromal malignant differentiation. Its tumorigenesis is associated with epithelial–mesenchymal transition (EMT), and phenotypic changes from carcinoma to sarcoma are associated with TP53 mutations. Case presentation. A 73-year-old female with bloody stool was diagnosed with rectal adenocarcinoma. She underwent trans-anal mucosal resection. Histopathologically, the tumor cells showed 2 morphologically distinct populations. One was composed of well-formed to fused glands or cribriform glands and was considered a moderately differentiated adenocarcinoma. The other consisted of pleomorphic discohesive atypical tumor cells with spindle and/or giant cell features, which was considered a sarcomatous tumor. Immunohistochemistry analysis showed that E-cadherin expression changed from positive to negative in the sarcomatous component. On the other hand, ZEB1 and SLUG were positive. Finally, she was diagnosed with carcinoma with a sarcomatoid component. We performed a mutation analysis by next genome sequencing and found KRAS and TP53 mutations in both carcinomatous and sarcomatous components. Conclusions. Immunohistochemistry and mutation analyses revealed tumorigenesis of rectal carcinoma with sarcomatoid components correlated with EMT and TP53 mutations.

1 August 2018 in World Neurosurgery
Verified
Journal Article
Closed access
YMYoshiyasu Matsumoto
Yoshiyasu Matsumoto
HKHiroshi Kashimura
Hiroshi Kashimura
KAKenta Aso
Kenta Aso
HSHiroaki Saura
Hiroaki Saura
MOMitsumasa Osakabe
Mitsumasa Osakabe
AKAkira Kurose
Akira Kurose

21 February 2022 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NYNaoki Yanagawa
Naoki Yanagawa
NUNoriyuki Uesugi
Noriyuki Uesugi
MNMASAO NISHIYA
MASAO NISHIYA
RSRyo Sugimoto
Ryo Sugimoto
MOMitsumasa Osakabe
Mitsumasa Osakabe
TSTamotsu Sugai
Tamotsu Sugai
Background: Low-grade fetal adenocarcinoma of the lung is a rare pulmonary tumor resembling fetal lung histologically. Due to its rarity, there is limited information regarding the pathogenesis and biological characteristics of low-grade fetal adenocarcinoma of the lung. Here, we describe two cases of low-grade fetal adenocarcinoma of the lung treated at our hospital and summarize cases of low-grade fetal adenocarcinoma of the lung reported in the literature. Case presentation: We examined two cases (one woman and one man; 30 and 67 years old, respectively). Histologically, tumor tissues from both cases had a complex glandular component with clear cuboidal and columnar cells that resembled the histological features of fetal lung. In some areas, squamous morules were prominent. Immunohistochemically, nuclear/cytoplasmic expression of β-catenin was detected in both cases. Mutation analysis revealed a CTNNB1 mutation in both cases and a DICER1 mutation in 1 case. No mutations in EGFR, BRAF, KRAS, or PIK3CA were found. Conclusions: Low-grade fetal adenocarcinoma of the lung showed a high frequency of CTNNB1 mutations and low frequencies of EGFR, KRAS, BRAF, and PIK3CA mutations in our examined cases and in previous studies. This rare tumor has unique clinicopathological characteristics with specific genetic aberrations involving the Wnt pathway. These results provide a molecular basis for development of new therapies to treat these tumors.

20 January 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YCYohei Chiba
Yohei Chiba
MKMasahiro Kagabu
Masahiro Kagabu
MOMitsumasa Osakabe
Mitsumasa Osakabe
RIRikako Ito
Rikako Ito
SSSho Sato
Sho Sato
TBTsukasa Baba
Tsukasa Baba
The Proactive Molecular Risk Classifier for Endometrial Cancer has identified four risk groups for the prognosis of endometrial cancer. Lenvatinib plus pembrolizumab was recently approved as a second-line treatment for unresectable endometrial cancer, but reports in clinical practice are lacking. The relationship between the efficacy of lenvatinib/pembrolizumab and Proactive Molecular Risk Classifier for Endometrial Cancer classification is unclear. This single-centre retrospective study included patients who underwent lenvatinib/pembrolizumab therapy at Iwate Medical University Hospital between January 2022 and March 2023. Formalin-fixed paraffin-embedded specimens obtained from patients before treatment were collected and classified into the mismatch repair-deficient, p53 abnormal and no specific molecular profile subtypes using immunohistochemistry. The response rate, progression-free survival and adverse events were evaluated using electronic medical records. The study was approved by the hospital’s ethics committee (approval number: MH2022-093). This study enrolled 20 patients, who underwent a median follow-up of 17.8 months (95% confidence interval: 16.6–18.9). The best overall response rate was 60.0% (36.1–80.9), and the median progression-free survival was 11.6 months (2.9–20.3). The median progression-free survival in the p53 abnormal group (n = 9) was 3.4 months (3.0–3.8); however, progression-free survival did not reach the median (P < 0.001) in the mismatch repair-deficient/no specific molecular profile group (n = 11). Symptomatic immune-related adverse events (except hypothyroidism) occurred in 4/20 (25.0%) patients, and partial responses were observed in all cases. No treatment-related deaths occurred. The p53abn group in the Proactive Molecular Risk Classifier for Endometrial Cancer classification has a poor prognosis even after treatment with lenvatinib/pembrolizumab.